Scholars Central

Conference abstractPublished 29 Feb 2016

Anaplastic thyroid cancer: Multimodal treatment results

Authors: Zaki Antonio Taissoun Aslan

Medellin Cancer Institute, Colombia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Anaplastic thyroid cancer is a rare and lethal disease. It accounts for 1-2% of thyroid malignancies, but specific mortality is higher than 90%. It is an aggressive loco-regional disease with a high metastatic capacity. There is no agreement concerning the best treatment. We analyzed the results of treatment in a Mestizo population treated in the National Cancer Institute (Mexico). Methods: 1,581 files of thyroid carcinomas were reviewed; of these, 29(1.83%) had anaplastic thyroid carcinoma. We analyzed Demographic variables, clinical manifestations, tumor characteristics and treatments. Results: The median age was 64.5±13.2 years. Females were more affected (female/male ratio: 2.6:1); 21 cases occurred in women (72.4%), and 8 in males (27.6%). The most common manifestations were neck enlargement (93.10%) and hoarseness (71.31%). The median tumor size was 8 cm (range: 4-20 cm). The percentage of cases, which presented in clinical stage IV-A was 10.3%, with 62.1% presenting in clinical stage IV-b and 27.6% presenting in clinical stage VI-c. Complete resection (R0) (p=0.05), radiation doses of higher than 33.1 Gy (p=0.04), and multimodal therapy were associated with better survival. Surgery plus radiotherapy with or without systemic treatment (p=0.006). The median overall survival was 119 days (IC 95%, 36.3-201.6). Six-month, one-year and two-year survival was 37.9%, 21% and 13%, respectively. Conclusion: Complete surgical resection is associated with better survival but is very difficult to achieve due to aggressive biological behavior. Multimodal therapy is associated with better survival and a better quality of life. There is a need for more effective systemic treatments as extensive surgical resections have little overall benefit in highly invasive and metastatic disease

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectDiabetes & Endocrinology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Zaki Antonio Taissoun Aslan”